Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Cost of Revenue: 2019-2024

Historic Cost of Revenue for Ascendis Pharma A (ASND) over the last 5 years, with Dec 2024 value amounting to $47.9 million.

  • Ascendis Pharma A's Cost of Revenue rose 112.44% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.1 million, marking a year-over-year increase of 76.83%. This contributed to the annual value of $47.9 million for FY2024, which is 0.28% up from last year.
  • Per Ascendis Pharma A's latest filing, its Cost of Revenue stood at $47.9 million for FY2024, which was up 0.28% from $47.8 million recorded in FY2023.
  • In the past 5 years, Ascendis Pharma A's Cost of Revenue registered a high of $47.9 million during FY2024, and its lowest value of $4.0 million during FY2021.
  • For the 3-year period, Ascendis Pharma A's Cost of Revenue averaged around $36.0 million, with its median value being $47.8 million (2023).
  • Data for Ascendis Pharma A's Cost of Revenue shows a peak YoY spiked of 285.75% (in 2023) over the last 5 years.
  • Over the past 4 years, Ascendis Pharma A's Cost of Revenue (Yearly) stood at $4.0 million in 2021, then skyrocketed by 207.25% to $12.4 million in 2022, then soared by 285.75% to $47.8 million in 2023, then climbed by 0.28% to $47.9 million in 2024.